Phibro Animal Health Corporation

NASDAQ:PAHC

Drug Manufacturers - Specialty & Generic

Healthcare
$35.57 +1.23%

+$0.38 today

Market cap
$1.44B
Beta
0.46
P/E (TTM)
13.3
EPS (TTM)
$2.35
Dividend yield
1.54%
52W Low $23.57High $60.08

Volume 0.11M

Average 0.37M

PAHC Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Phibro Animal Health CorporationNASDAQ: PAHC

Gross Profit · Q3 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q3 FY2026 gross profit of $124.87M rose 19.4% year over year, behind the +29.2% change in trailing-twelve-month gross profit. Sequentially, it fell 5.9% from the prior quarter. Over 3 fiscal years it compounded at +11.9% a year.

Context

  • Gross profit amounted to 30.9% of revenue in FY2025, unchanged from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +19.4% toward the trailing-twelve-month pace of +29.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$124.87M-5.9% QoQ
Last fiscal yearJun 2025
$399.94M+27.7% YoY
LTMMar 2026
$487.32M+29.2% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.4%——
1 year+27.7%——
3-year CAGR+11.9%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
399.94M USD
Year-over-year change
+27.7%
4-year CAGR
+10.2%

Gross Profit vs competitors

How PAHC compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +29.2% is the 2nd highest of 6, against a peer median of +4.1%.
  • Gross profit amounts to 32.5% of revenue for PAHC, versus a peer median of 53.5%.
PAHC Competitors
Gross Profit for PAHC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$50.05B USD+4.1%+3.7%75.4%
ZTSZoetis Inc.LTM Jun 2026$6.75B USD+2.6%+6.8%70.9%
ELANElanco Animal Health IncorporatedLTM Sep 2026$2.75B USD+29.3%+1.3%53.5%
PAHCPhibro Animal Health CorporationLTM Mar 2026$487.32M USD+29.2%+11.9%32.5%
NEOGNeogen CorporationLTM Aug 2026$418.98M USD+14.9%+0.2%47.4%
ZYBTZhengye Biotechnology Holding LimitedFY2025CN¥23.87M CNY-73.9%-46.2%20.5%
Peer median (excluding PAHC) —+4.1%+1.3%53.5%

Competitors are the stored peer set for PAHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue833.35M942.26M977.89M1.02B1.3B
Cost of Revenue561.97M656.86M679.65M704.59M896.27M
Gross Profit271.38M285.4M298.24M313.09M399.94M
Gross Margin32.6%30.3%30.5%30.8%30.9%
Research & Development00000
Selling, General & Admin196.51M206.41M226.39M259.78M289.48M
Operating Expenses196.51M206.41M226.39M259.78M289.48M
Depreciation & Amortization31.88M32.71M34.01M36.18M45.61M
EBITDA110.21M117.13M106.03M69.06M146.85M
EBITDA Margin13.2%12.4%10.8%6.8%11.3%
Operating Income74.87M78.99M71.85M53.32M110.47M
Operating Margin9.0%8.4%7.3%5.2%8.5%
Interest Income838K816K3.36M4.47M2.62M
Interest Expense10.4M12.1M17.95M21.97M33.25M
Other Income / Expenses(8.4M)(6.66M)(17.78M)(42.4M)(42.47M)
Income Before Tax66.47M72.33M54.07M10.92M67.99M
Pre-Tax Margin8.0%7.7%5.5%1.1%5.2%
Income Tax Expense12.08M23.15M21.47M8.5M19.73M
Net Income54.39M49.18M32.61M2.42M48.26M
Net Margin6.5%5.2%3.3%0.2%3.7%
EPS (Basic)1.341.210.810.061.19
EPS (Diluted)1.341.210.810.061.19
Weighted Avg Shares40.5M40.5M40.5M40.5M40.5M
Weighted Avg Shares (Diluted)40.5M40.5M40.5M40.52M40.7M

Phibro Animal Health Corporation

NASDAQ:PAHC

Intrinsic Alpha fair value

Locked

Current Price

$35.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.